skip to main content
Tipo de recurso Mostra resultados com: Mostra resultados com: Índice

Intravesical administration of small interfering RNA targeting PLK-1 successfully prevents the growth of bladder cancer

Nogawa, Masaki ; Yuasa, Takeshi ; Kimura, Shinya ; Tanaka, Motoyoshi ; Kuroda, Junya ; Sato, Kiyoshi ; Yokota, Asumi ; Segawa, Hidekazu ; Toda, Yoshinobu ; Kageyama, Susumu ; Yoshiki, Tatsuhiro ; Okada, Yusaku ; Maekawa, Taira

The Journal of clinical investigation, 2005-03, Vol.115 (4), p.978-985 [Periódico revisado por pares]

American Society for Clinical Investigation

Texto completo disponível

Citações Citado por
  • Título:
    Intravesical administration of small interfering RNA targeting PLK-1 successfully prevents the growth of bladder cancer
  • Autor: Nogawa, Masaki ; Yuasa, Takeshi ; Kimura, Shinya ; Tanaka, Motoyoshi ; Kuroda, Junya ; Sato, Kiyoshi ; Yokota, Asumi ; Segawa, Hidekazu ; Toda, Yoshinobu ; Kageyama, Susumu ; Yoshiki, Tatsuhiro ; Okada, Yusaku ; Maekawa, Taira
  • É parte de: The Journal of clinical investigation, 2005-03, Vol.115 (4), p.978-985
  • Notas: Address correspondence to: Takeshi Yuasa, Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital, 54 Shogoin-Kawahara, Sakyo-ku, Kyoto 606-8507, Japan. Phone: 81-75-751-3630; Fax: 81-75-751-3631; E-mail: yuasa@kuhp.kyoto-u.ac.jp.
  • Descrição: The mainstay in the management of invasive bladder cancer continues to be radical cystectomy. With regard to improvement of quality of life, however, therapies that preserve the bladder are desirable. We investigated the use of intravesical PLK-1 small interfering RNA (siRNA) against bladder cancer. Patients with bladder cancers expressing high levels of PLK-1 have a poor prognosis compared with patients with low expression. Using siRNA/cationic liposomes, the expression of endogenous PLK-1 could be suppressed in bladder cancer cells in a time- and dose-dependent manner. As a consequence, PLK-1 functions were disrupted. Inhibition of bipolar spindle formation, accumulation of cyclin B1, reduced cell proliferation, and induction of apoptosis were observed. In order to determine the efficacy of the siRNA/liposomes in vivo, we established an orthotopic mouse model using a LUC-labeled bladder cancer cell line, UM-UC-3 LUC . PLK-1 siRNA was successfully transfected into the cells, reduced PLK-1 expression, and prevented the growth of bladder cancer in this mouse model. This is the first demonstration, to our knowledge, of inhibition of cancer growth in the murine bladder by intravesical siRNA/cationic liposomes. We believe intravesical siRNA instillation against bladder cancer will be useful as a therapeutic tool.
  • Editor: American Society for Clinical Investigation
  • Idioma: Inglês

Buscando em bases de dados remotas. Favor aguardar.